View Future GrowthMultiQure 과거 순이익 실적과거 기준 점검 0/6MultiQure은 연평균 8.2%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 17%의 비율로 증가했습니다. 매출은 연평균 26.4%의 비율로 감소했습니다.핵심 정보8.20%순이익 성장률24.56%주당순이익(EPS) 성장률Biotechs 산업 성장률-14.59%매출 성장률-26.36%자기자본이익률n/a순이익률n/a다음 순이익 업데이트30 Sep 2026최근 과거 실적 업데이트공고 • Nov 11Pure Biologics S.A. to Report Q3, 2025 Results on Nov 14, 2025Pure Biologics S.A. announced that they will report Q3, 2025 results on Nov 14, 2025공고 • Aug 21Pure Biologics S.A. to Report First Half, 2025 Results on Sep 15, 2025Pure Biologics S.A. announced that they will report first half, 2025 results on Sep 15, 2025공고 • Jan 30+ 2 more updatesPure Biologics S.A. to Report First Half, 2024 Results on Sep 16, 2024Pure Biologics S.A. announced that they will report first half, 2024 results on Sep 16, 2024Reported Earnings • Nov 19Third quarter 2023 earnings released: zł2.36 loss per share (vs zł2.85 loss in 3Q 2022)Third quarter 2023 results: zł2.36 loss per share. Net loss: zł7.60m (loss widened 18% from 3Q 2022).Reported Earnings • Sep 03Second quarter 2023 earnings releasedSecond quarter 2023 results: Net loss: zł9.92m (loss widened 75% from 2Q 2022).Reported Earnings • May 21First quarter 2023 earnings released: zł2.29 loss per share (vs zł2.82 loss in 1Q 2022)First quarter 2023 results: zł2.29 loss per share. Net loss: zł7.04m (loss widened 11% from 1Q 2022).모든 업데이트 보기Recent updates공고 • Jun 04Pure Biologics S.A., Annual General Meeting, Jun 29, 2026Pure Biologics S.A., Annual General Meeting, Jun 29, 2026, at 11:00 Central European Standard Time.New Risk • Dec 02New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 118% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł6.6m free cash flow). Shares are highly illiquid. Negative equity (-zł18m). Earnings have declined by 6.0% per year over the past 5 years. Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€7.85m market cap, or US$9.12m).공고 • Nov 11Pure Biologics S.A. to Report Q3, 2025 Results on Nov 14, 2025Pure Biologics S.A. announced that they will report Q3, 2025 results on Nov 14, 2025공고 • Aug 21Pure Biologics S.A. to Report First Half, 2025 Results on Sep 15, 2025Pure Biologics S.A. announced that they will report first half, 2025 results on Sep 15, 2025공고 • Jun 05Pure Biologics S.A., Annual General Meeting, Jun 28, 2024Pure Biologics S.A., Annual General Meeting, Jun 28, 2024.공고 • Jan 30+ 2 more updatesPure Biologics S.A. to Report First Half, 2024 Results on Sep 16, 2024Pure Biologics S.A. announced that they will report first half, 2024 results on Sep 16, 2024Reported Earnings • Nov 19Third quarter 2023 earnings released: zł2.36 loss per share (vs zł2.85 loss in 3Q 2022)Third quarter 2023 results: zł2.36 loss per share. Net loss: zł7.60m (loss widened 18% from 3Q 2022).Reported Earnings • Sep 03Second quarter 2023 earnings releasedSecond quarter 2023 results: Net loss: zł9.92m (loss widened 75% from 2Q 2022).Reported Earnings • May 21First quarter 2023 earnings released: zł2.29 loss per share (vs zł2.82 loss in 1Q 2022)First quarter 2023 results: zł2.29 loss per share. Net loss: zł7.04m (loss widened 11% from 1Q 2022).공고 • May 09Pure Biologics Spólka Akcyjna, Annual General Meeting, May 25, 2023Pure Biologics Spólka Akcyjna, Annual General Meeting, May 25, 2023, at 12:00 Central European Standard Time.공고 • Feb 03+ 3 more updatesPure Biologics Spólka Akcyjna to Report Q3, 2023 Results on Nov 15, 2023Pure Biologics Spólka Akcyjna announced that they will report Q3, 2023 results on Nov 15, 2023Reported Earnings • Sep 18Second quarter 2022 earnings released: zł2.51 loss per share (vs zł1.63 loss in 2Q 2021)Second quarter 2022 results: zł2.51 loss per share (further deteriorated from zł1.63 loss in 2Q 2021). Revenue: zł6.41m (up zł6.34m from 2Q 2021). Net loss: zł5.66m (loss widened 55% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.공고 • May 25Pure Biologics Spólka Akcyjna, Annual General Meeting, Jun 23, 2022Pure Biologics Spólka Akcyjna, Annual General Meeting, Jun 23, 2022, at 10:00 Central European Standard Time.Reported Earnings • Apr 02Full year 2021 earnings released: zł5.22 loss per share (vs zł7.11 loss in FY 2020)Full year 2021 results: zł5.22 loss per share. Revenue: zł18.0m (up zł17.5m from FY 2020). Net loss: zł11.8m (flat on FY 2020). Over the next year, revenue is expected to shrink by 97% compared to a 129% growth forecast for the pharmaceuticals industry in Germany.Reported Earnings • Nov 19Third quarter 2021 earnings released: zł2.02 loss per share (vs zł1.60 loss in 3Q 2020)Third quarter 2021 results: Net loss: zł4.28m (loss widened 62% from 3Q 2020).Reported Earnings • Sep 15Second quarter 2021 earnings released: zł1.63 loss per share (vs zł1.59 loss in 2Q 2020)Second quarter 2021 results: Net loss: zł3.66m (loss widened 39% from 2Q 2020).공고 • Feb 02+ 1 more updatePure Biologics Spólka Akcyjna to Report Q3, 2021 Results on Nov 15, 2021Pure Biologics Spólka Akcyjna announced that they will report Q3, 2021 results on Nov 15, 2021공고 • Feb 01+ 1 more updatePure Biologics Spólka Akcyjna to Report First Half, 2021 Results on Sep 20, 2021Pure Biologics Spólka Akcyjna announced that they will report first half, 2021 results on Sep 20, 2021Is New 90 Day High Low • Jan 09New 90-day high: €25.80The company is up 45% from its price of €17.80 on 09 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period.Is New 90 Day High Low • Nov 17New 90-day high: €25.00The company is up 7.0% from its price of €23.40 on 19 August 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period.Reported Earnings • Nov 16Third quarter 2020 earnings released: zł1.60 loss per shareThird quarter 2020 results: Net loss: zł2.64m (loss widened 180% from 3Q 2019).Is New 90 Day High Low • Oct 30New 90-day low: €15.05The company is down 33% from its price of €22.50 on 31 July 2020. The German market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 14% over the same period.Is New 90 Day High Low • Sep 26New 90-day low: €18.25The company is down 14% from its price of €21.10 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.매출 및 비용 세부 내역MultiQure가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BST:PQB 매출, 비용 및 순이익 (PLN Millions)날짜매출순이익일반관리비연구개발비31 Mar 260-97031 Dec 250-86030 Sep 250-1315030 Jun 250-1315031 Mar 250-1214031 Dec 240-1315030 Sep 24-11-1918030 Jun 240-1518031 Mar 240-612031 Dec 230-1018030 Sep 2311-413030 Jun 230-1319031 Mar 231-2630031 Dec 221-2629030 Sep 221-1926030 Jun 221-1724031 Mar 220-1522031 Dec 210-1221030 Sep 210-1529-1330 Jun 210-1427-831 Mar 210-1324-431 Dec 201-1220030 Sep 201-981630 Jun 201-771531 Mar 202-641631 Dec 192-451230 Sep 192-36930 Jun 192-25631 Mar 192-18031 Dec 181-16030 Sep 18104031 Dec 17101031 Dec 161010양질의 수익: PQB 은(는) 현재 수익성이 없습니다.이익 마진 증가: PQB는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: PQB는 수익성이 없지만 지난 5년 동안 연평균 8.2%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 PQB의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: PQB은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(1.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: PQB의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/12 15:02종가2026/08/12 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스MultiQure S.A.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Sylwia JaskiewiczDom Maklerski Banku Ochrony Srodowiska S.A.
공고 • Nov 11Pure Biologics S.A. to Report Q3, 2025 Results on Nov 14, 2025Pure Biologics S.A. announced that they will report Q3, 2025 results on Nov 14, 2025
공고 • Aug 21Pure Biologics S.A. to Report First Half, 2025 Results on Sep 15, 2025Pure Biologics S.A. announced that they will report first half, 2025 results on Sep 15, 2025
공고 • Jan 30+ 2 more updatesPure Biologics S.A. to Report First Half, 2024 Results on Sep 16, 2024Pure Biologics S.A. announced that they will report first half, 2024 results on Sep 16, 2024
Reported Earnings • Nov 19Third quarter 2023 earnings released: zł2.36 loss per share (vs zł2.85 loss in 3Q 2022)Third quarter 2023 results: zł2.36 loss per share. Net loss: zł7.60m (loss widened 18% from 3Q 2022).
Reported Earnings • Sep 03Second quarter 2023 earnings releasedSecond quarter 2023 results: Net loss: zł9.92m (loss widened 75% from 2Q 2022).
Reported Earnings • May 21First quarter 2023 earnings released: zł2.29 loss per share (vs zł2.82 loss in 1Q 2022)First quarter 2023 results: zł2.29 loss per share. Net loss: zł7.04m (loss widened 11% from 1Q 2022).
공고 • Jun 04Pure Biologics S.A., Annual General Meeting, Jun 29, 2026Pure Biologics S.A., Annual General Meeting, Jun 29, 2026, at 11:00 Central European Standard Time.
New Risk • Dec 02New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 118% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł6.6m free cash flow). Shares are highly illiquid. Negative equity (-zł18m). Earnings have declined by 6.0% per year over the past 5 years. Shareholders have been substantially diluted in the past year (118% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€7.85m market cap, or US$9.12m).
공고 • Nov 11Pure Biologics S.A. to Report Q3, 2025 Results on Nov 14, 2025Pure Biologics S.A. announced that they will report Q3, 2025 results on Nov 14, 2025
공고 • Aug 21Pure Biologics S.A. to Report First Half, 2025 Results on Sep 15, 2025Pure Biologics S.A. announced that they will report first half, 2025 results on Sep 15, 2025
공고 • Jun 05Pure Biologics S.A., Annual General Meeting, Jun 28, 2024Pure Biologics S.A., Annual General Meeting, Jun 28, 2024.
공고 • Jan 30+ 2 more updatesPure Biologics S.A. to Report First Half, 2024 Results on Sep 16, 2024Pure Biologics S.A. announced that they will report first half, 2024 results on Sep 16, 2024
Reported Earnings • Nov 19Third quarter 2023 earnings released: zł2.36 loss per share (vs zł2.85 loss in 3Q 2022)Third quarter 2023 results: zł2.36 loss per share. Net loss: zł7.60m (loss widened 18% from 3Q 2022).
Reported Earnings • Sep 03Second quarter 2023 earnings releasedSecond quarter 2023 results: Net loss: zł9.92m (loss widened 75% from 2Q 2022).
Reported Earnings • May 21First quarter 2023 earnings released: zł2.29 loss per share (vs zł2.82 loss in 1Q 2022)First quarter 2023 results: zł2.29 loss per share. Net loss: zł7.04m (loss widened 11% from 1Q 2022).
공고 • May 09Pure Biologics Spólka Akcyjna, Annual General Meeting, May 25, 2023Pure Biologics Spólka Akcyjna, Annual General Meeting, May 25, 2023, at 12:00 Central European Standard Time.
공고 • Feb 03+ 3 more updatesPure Biologics Spólka Akcyjna to Report Q3, 2023 Results on Nov 15, 2023Pure Biologics Spólka Akcyjna announced that they will report Q3, 2023 results on Nov 15, 2023
Reported Earnings • Sep 18Second quarter 2022 earnings released: zł2.51 loss per share (vs zł1.63 loss in 2Q 2021)Second quarter 2022 results: zł2.51 loss per share (further deteriorated from zł1.63 loss in 2Q 2021). Revenue: zł6.41m (up zł6.34m from 2Q 2021). Net loss: zł5.66m (loss widened 55% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
공고 • May 25Pure Biologics Spólka Akcyjna, Annual General Meeting, Jun 23, 2022Pure Biologics Spólka Akcyjna, Annual General Meeting, Jun 23, 2022, at 10:00 Central European Standard Time.
Reported Earnings • Apr 02Full year 2021 earnings released: zł5.22 loss per share (vs zł7.11 loss in FY 2020)Full year 2021 results: zł5.22 loss per share. Revenue: zł18.0m (up zł17.5m from FY 2020). Net loss: zł11.8m (flat on FY 2020). Over the next year, revenue is expected to shrink by 97% compared to a 129% growth forecast for the pharmaceuticals industry in Germany.
Reported Earnings • Nov 19Third quarter 2021 earnings released: zł2.02 loss per share (vs zł1.60 loss in 3Q 2020)Third quarter 2021 results: Net loss: zł4.28m (loss widened 62% from 3Q 2020).
Reported Earnings • Sep 15Second quarter 2021 earnings released: zł1.63 loss per share (vs zł1.59 loss in 2Q 2020)Second quarter 2021 results: Net loss: zł3.66m (loss widened 39% from 2Q 2020).
공고 • Feb 02+ 1 more updatePure Biologics Spólka Akcyjna to Report Q3, 2021 Results on Nov 15, 2021Pure Biologics Spólka Akcyjna announced that they will report Q3, 2021 results on Nov 15, 2021
공고 • Feb 01+ 1 more updatePure Biologics Spólka Akcyjna to Report First Half, 2021 Results on Sep 20, 2021Pure Biologics Spólka Akcyjna announced that they will report first half, 2021 results on Sep 20, 2021
Is New 90 Day High Low • Jan 09New 90-day high: €25.80The company is up 45% from its price of €17.80 on 09 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Nov 17New 90-day high: €25.00The company is up 7.0% from its price of €23.40 on 19 August 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period.
Reported Earnings • Nov 16Third quarter 2020 earnings released: zł1.60 loss per shareThird quarter 2020 results: Net loss: zł2.64m (loss widened 180% from 3Q 2019).
Is New 90 Day High Low • Oct 30New 90-day low: €15.05The company is down 33% from its price of €22.50 on 31 July 2020. The German market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 14% over the same period.
Is New 90 Day High Low • Sep 26New 90-day low: €18.25The company is down 14% from its price of €21.10 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.